Home » GVAX IMPROVES SURVIVAL IN METASTATIC HORMONE-REFRACTORY PROSTATE CANCER
GVAX IMPROVES SURVIVAL IN METASTATIC HORMONE-REFRACTORY PROSTATE CANCER
Researchers have reported that the investigative immunotherapy agent GVAX improves predicted survival time with little toxicity in patients with metastatic hormone-refractory prostate cancer (HRPC). These results from two phase II trials were presented at the 2006 annual meeting of the American Urological Association
CancerConsultants.com
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May